(Q40237044)

18 September 2017

0 references

Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries (English)

1 reference

pneumococcal conjugate vaccine

18 September 2017

main subject

1 reference

7

William C Gruber

1 reference

18 September 2017

Allison Thompson

1

1 reference

18 September 2017

Alejandra Gurtman

2

1 reference

18 September 2017

Scott Patterson

3

1 reference

18 September 2017

Christine Juergens

4

1 reference

18 September 2017

France Laudat

5

1 reference

18 September 2017

Emilio A Emini

6

1 reference

18 September 2017

Daniel A Scott

8

1 reference

18 September 2017

language of work or name

English

0 references

publication date

20 August 2013

1 reference

18 September 2017

1 reference

18 September 2017

volume

31

1 reference

18 September 2017

issue

45

1 reference

18 September 2017

page(s)

5289-5295

1 reference

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.025

Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.025

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.025

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.025

Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.025

Safety experience with heptavalent pneumococcal CRM197-conjugate vaccine (Prevenar) since vaccine introduction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.025

Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.025

Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.025

Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.025

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.025

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.025

International trends in sudden infant death syndrome: stabilization of rates requires further action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.025

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.025

10.1016/J.VACCINE.2013.08.025

7 January 2021

Identifiers

DOI

1 reference

18 September 2017

1 reference